Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Treasury Shares: 2016-2024

Historic Treasury Shares for Seres Therapeutics (MCRB) over the last 9 years, with Dec 2024 value amounting to $81,459.

  • Seres Therapeutics' Treasury Shares fell 96.34% to $100,824 in Q3 2025 from the same period last year, while for Sep 2025 it was $100,824, marking a year-over-year decrease of 96.34%. This contributed to the annual value of $81,459 for FY2024, which is 97.59% down from last year.
  • Latest data reveals that Seres Therapeutics reported Treasury Shares of $81,459 as of FY2024, which was down 97.59% from $3.4 million recorded in FY2023.
  • In the past 5 years, Seres Therapeutics' Treasury Shares ranged from a high of $3.4 million in FY2023 and a low of $6,500 during FY2020.
  • For the 3-year period, Seres Therapeutics' Treasury Shares averaged around $1.7 million, with its median value being $1.5 million (2022).
  • Per our database at Business Quant, Seres Therapeutics' Treasury Shares spiked by 11,203.92% in 2021 and then plummeted by 97.59% in 2024.
  • Seres Therapeutics' Treasury Shares (Yearly) stood at $6,500 in 2020, then skyrocketed by 11,203.92% to $734,755 in 2021, then spiked by 110.89% to $1.5 million in 2022, then surged by 117.99% to $3.4 million in 2023, then slumped by 97.59% to $81,459 in 2024.